Indeloxazine

Indeloxazine hydrochloride is a racemic morpholine derivative, chemically 2-[(3H-inden-4-yloxy)methyl]morpholine, that Yamanouchi Pharmaceutical brought to market in Japan in 1988. It belongs to the loose Japanese drug category of nao daisha kaizen yaku, cerebral metabolism and circulation improvers, and was indicated for the psychiatric sequelae of cerebrovascular disease: post-stroke depression, reduced motivation and emotional lability. It reached pharmacies as Elen and Noin, typically as 20 mg tablets ^[14].

Mechanistically it is best described as a serotonin and norepinephrine reuptake inhibitor with an added serotonin-releasing action. In rat cortical membranes it shows preferential affinity for the serotonin transporter (Ki near 22 nM against [3H]citalopram) and the norepinephrine transporter (Ki near 19 nM against [3H]nisoxetine), and microdialysis in freely moving rats confirms that systemic dosing raises extracellular serotonin and norepinephrine in the frontal cortex; it also directly enhances spontaneous serotonin release from cortical synaptosomes, which sets it apart from a plain reuptake blocker ^[1].A second thread of its pharmacology is cholinergic. Indeloxazine raises acetylcholine output in the frontal cortex, and this effect depends on endogenous serotonin acting downstream on 5-HT4 receptors rather than on any direct action at the cholinergic synapse ^[2]. In animal learning models it partially reversed passive-avoidance deficits produced by scopolamine, cholinotoxin lesions and nucleus basalis damage, effects the investigators linked to this indirect cholinergic facilitation ^[3]. Reports also describe it enhancing long-term potentiation and, in the older literature, acting as an NMDA receptor antagonist, though the reuptake and release actions are the best documented.

Much of the preclinical case for a stroke indication rested on anti-ischemic and metabolic findings. Indeloxazine and its optical isomers prolonged survival under hypoxia and raised brain glucose and ATP together with local cerebral glucose utilization, effects not shared by selective monoamine uptake inhibitors ^[4]. In gerbils, pre-treatment before transient forebrain ischemia improved survival of hippocampal CA1 pyramidal neurons, an effect the authors tied to a higher pre-ischemic energy state; post-treatment alone did not protect ^[5]. It also blunted kindled amygdaloid seizures at low doses while provoking convulsions at high doses ^[6], and improved passive-avoidance performance after fluid-percussion traumatic brain injury ^[7].

The clinical story is thin by modern standards. The stroke-recovery indication was supported largely by small Japanese trials from the 1980s and by this animal pharmacology, and it was never a robust evidence base. When Japanese regulators re-examined the class of cerebral activators, indeloxazine was judged to lack demonstrated efficacy and was removed from the market in 1998, the same reassessment that culled several neighbouring agents.

The compound had a second life in the laboratory. Astellas resolved the racemate and took forward the (+)-isomer as AS1069562, the (R)-enantiomer, as a candidate analgesic. In rat chronic constriction injury, streptozotocin diabetic neuropathy and arthritis models it relieved allodynia and hyperalgesia comparably to duloxetine, but with a striking twist: its analgesia persisted for up to a day, and in the diabetic model for a week, after plasma levels had fallen below detection, an effect linked to restored neurotrophic factor expression rather than to ongoing transporter blockade ^[8][9]. Its broad action was traced to affinity at 5-HT1A and 5-HT3 receptors on top of transporter inhibition ^[10][11], and serotonin transporter occupancy above roughly 70 percent was needed for analgesia in a fibromyalgia-like model ^[12].

Human safety data are limited and dated, drawn mainly from its decade on the Japanese market rather than from modern controlled trials. The clearest documented adverse reaction is dermatologic: a case report describes indeloxazine triggering a widespread eruption with eosinophilia that on patch and challenge testing had the features of eosinophilic pustular folliculitis, the first such drug-induced case reported ^[13]. By its monoaminergic mechanism, effects in the family of nausea, appetite change, insomnia, agitation and restlessness are plausible, but a well-characterised human adverse-event profile is not available in the accessible literature.

In animal seizure work, low doses suppressed kindled seizures while a high dose induced generalized convulsions, hinting at a dose-dependent proconvulsant risk at supratherapeutic exposure ^[6]. It was ultimately withdrawn for lack of demonstrated efficacy rather than for a safety signal. Interactions with other serotonergic or noradrenergic drugs would be expected on mechanistic grounds but have not been formally mapped.

Indeloxazine was synthesized and developed by Yamanouchi Pharmaceutical (later part of Astellas) under the codes YM-08054 and CI-874. It launched in Japan in 1988 as Elen and Noin, marketed as a cerebral activator for the depression, avolition and emotional disturbance that accompany cerebrovascular disease, and was also sold in South Korea. Its approval sat within a Japanese regulatory category of cerebral metabolism and circulation improvers that flourished in the 1980s and was later scrutinised heavily.

In 1998, a re-evaluation of these agents concluded that indeloxazine had not shown convincing efficacy, and it was removed from the market. Years later Astellas returned to the molecule, resolved the racemate, and advanced the (+)-isomer as AS1069562 (the (R)-enantiomer, a monobenzenesulfonate salt) as an investigational treatment for neuropathic and inflammatory pain; the published record on that program is preclinical, centred on a cluster of Astellas rat and mouse studies from 2013 to 2015 ^{[8][9][10][11][12]}.

Indeloxazine is an obscure, historical drug rather than a current clinical or nootropics-community staple. Among people who track old Japanese cerebral activators it is remembered alongside bifemelane, idebenone and aniracetam as part of a cohort that was widely prescribed and then largely discredited when regulators demanded stronger efficacy evidence. It has little presence in Western nootropics use, partly because it was never approved outside East Asia and was withdrawn decades ago. Its more interesting modern reputation is as the parent of AS1069562, a reminder that a shelved racemate can hold a single enantiomer worth revisiting; the pain-model finding that its analgesia outlasts measurable drug exposure is the detail that draws the most attention.